{"id":111457,"date":"2025-11-18T06:41:11","date_gmt":"2025-11-18T06:41:11","guid":{"rendered":"https:\/\/insights.greyb.com\/?post_type=ht_kb&p=111457"},"modified":"2025-11-20T10:19:35","modified_gmt":"2025-11-20T10:19:35","slug":"metacrine-patents","status":"publish","type":"ht_kb","link":"https:\/\/insights.greyb.com\/metacrine-patents\/","title":{"rendered":"Metacrine Patents – Insights & Stats (Updated 2025)"},"content":{"rendered":"\n

Metacrine has a total of 121 patents globally, out of which 8 have been granted. Of these 121 patents, more than 24% patents are active. The United States of America is where Metacrine has filed the maximum number of patents. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Metacrine.<\/p>\n\n\n\n

Metacrine was founded in 2014. Metacrine is a clinical-stage biopharmaceutical company dedicated to developing differentiated treatments for liver and gastrointestinal disorders. Its work centers on targeting the farnesoid X receptor (FXR), a key regulator of liver and GI disease processes. The company\u2019s FXR-focused pipeline includes the product candidates MET409 and MET642.<\/p>\n\n\n\n

Do read about some of the most popular patents of Metacrine which have been covered by us in this article and also you can find Metacrine patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Metacrine patent portfolio.<\/p>\n\n\n\n

How many patents does <\/strong>Metacrine <\/strong>have?<\/strong><\/h3>\n\n\n\n

Metacrine has a total of 121 patents globally. These patents belong to 22 unique patent families. Out of 121 patents, 30 patents are active.<\/p>\n\n\n\n

How Many Patents did Metacrine File Every Year?<\/strong><\/h3>\n\n\n\n
\"Metacrine<\/a><\/figure>\n\n\n\n

Are you wondering why there is a drop in patent filing for the last two years? <\/strong>It is because a patent application can take up to 18 months to get published. Certainly, it doesn\u2019t suggest a decrease in the patent filing.<\/p>\n\n\n\n

Year of Patents Filing or Grant<\/strong><\/td>Metacrine<\/strong> <\/strong>Applications Filed<\/strong><\/td>Metacrine Patents Granted<\/strong><\/td><\/tr>
2025<\/td>–<\/td>2<\/td><\/tr>
2022<\/td>3<\/td>3<\/td><\/tr>
2021<\/td>35<\/td>1<\/td><\/tr>
2020<\/td>1<\/td>1<\/td><\/tr>
2019<\/td>48<\/td>1<\/td><\/tr>
2018<\/td>16<\/td>–<\/td><\/tr>
2017<\/td>2<\/td>–<\/td><\/tr>
2016<\/td>16<\/td>–<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

How many <\/strong>Metacrine <\/strong>patents are Alive\/Dead?<\/strong><\/h3>\n\n\n\n

Worldwide Patents<\/strong><\/p>\n\n\n\n

\"Metacrine<\/a><\/figure>\n\n\n\n

How Many Patents did Metacrine File in Different Countries?<\/strong><\/h3>\n\n\n\n
\"Metacrine<\/a><\/figure>\n\n\n\n

Countries in which Metacrine Filed Patents<\/strong><\/h3>\n\n\n\n
Country<\/strong><\/td>Patents<\/strong><\/td><\/tr>
United States of America<\/td>14<\/td><\/tr>
India<\/td>8<\/td><\/tr>
Europe (EPO)<\/td>8<\/td><\/tr>
Japan<\/td>8<\/td><\/tr>
Canada<\/td>7<\/td><\/tr>
Eurasia<\/td>6<\/td><\/tr>
Korea (South)<\/td>5<\/td><\/tr>
Brazil<\/td>5<\/td><\/tr>
Argentina<\/td>5<\/td><\/tr>
China<\/td>5<\/td><\/tr>
Mexico<\/td>4<\/td><\/tr>
Hong Kong (S.A.R.)<\/td>4<\/td><\/tr>
Singapore<\/td>4<\/td><\/tr>
Taiwan<\/td>3<\/td><\/tr>
Australia<\/td>3<\/td><\/tr>
Israel<\/td>3<\/td><\/tr>
Chile<\/td>1<\/td><\/tr>
Philippines<\/td>1<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Where are Research Centers <\/strong>of <\/strong>Metacrine <\/strong>Patents <\/strong>Located?<\/strong><\/h3>\n\n\n\n

The Research Centers of Metacrine Patents is the United States of America.<\/p>\n\n\n\n

10 Best <\/strong>Metacrine <\/strong>Patents<\/strong><\/strong><\/h3>\n\n\n\n

WO2017049173A1<\/a> is the most popular patent in the Metacrine portfolio. It has received 75 citations so far from companies like Bristol-Myers Squibb Company, Enyo Pharma, Tenaya Therapeutics.<\/p>\n\n\n\n

Below is the list of 10 most cited patents of Metacrine:<\/strong><\/h3>\n\n\n\n
Publication Number<\/strong><\/td>Citation Count<\/strong><\/td><\/tr>
WO2017049173A1<\/a><\/td>75<\/td><\/tr>
WO2018170182A1<\/a><\/td>65<\/td><\/tr>
WO2018170166A1<\/a><\/td>57<\/td><\/tr>
WO2018170173A1<\/a><\/td>56<\/td><\/tr>
WO2017049177A1<\/a><\/td>48<\/td><\/tr>
WO2017049176A1<\/a><\/td>47<\/td><\/tr>
WO2018170165A1<\/a><\/td>38<\/td><\/tr>
WO2017049172A1<\/a><\/td>33<\/td><\/tr>
WO2018170167A1<\/a><\/td>32<\/td><\/tr>
WO2020061114A1<\/a><\/td>31<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

What are Metacrine key innovation segments?<\/strong><\/h3>\n\n\n\n\n